The cellular sources of interleukin 6 (IL-6) that are relevant for differentiation of the T H 17 subset of helper T cells remain unclear. Here we used a novel strategy for the conditional deletion of distinct IL-6-producing cell types to show that dendritic cells (DCs) positive for the signaling regulator Sirpa were essential for the generation of pathogenic T H 17 cells. Using their IL-6 receptor a-chain (IL-6Ra), Sirpa + DCs trans-presented IL-6 to T cells during the process of cognate interaction. While ambient IL-6 was sufficient to suppress the induction of expression of the transcription factor Foxp3 in T cells, trans-presentation of IL-6 by DC-bound IL-6Ra (called 'IL-6 cluster signaling' here) was needed to prevent premature induction of interferon-g (IFN-g) expression in T cells and to generate pathogenic T H 17 cells in vivo. Our findings should guide therapeutic approaches for the treatment of T H 17-cell-mediated autoimmune diseases.
During antigen-specific priming, CD4 + helper T cells differentiate into distinct subsets characterized by specific master transcription factors and signature cytokines. The differentiation process is controlled by various cytokines present in the micro-environment, in which CD4 + T cells interact in a cognate way with antigen-presenting cells (APCs). Because stimulation of the T cell antigen receptor (TCR) in the presence of the ubiquitously expressed cytokine TGFβ results in the induction of expression of the transcription factor Foxp3, productive effector T cell responses require efficient ways to suppress such induction in T cells during priming. Although interleukin 27 (IL-27) has additional regulatory functions 1 , IL-27 and IL-4 are strong inhibitors of the induction of Foxp3 expression during the development of T H 1 cells and T H 2 cells, respectively [2] [3] [4] . During T H 17 cell development, IL-6 prevents transcription of the gene encoding Foxp3 and at the same time induces 6) . However, it is unclear whether these functions of IL-6 are connected with each other or are independent events.
T H 17 cells are categorized as pathogenic or non-pathogenic depending on whether or not they have sensed IL- 23 (refs. 7,8) . However, single-cell analysis of T H 17 cells isolated from the inflamed central nervous system (CNS) has revealed that individual T H 17 cells can exhibit a non-pathogenic gene signature, including the expression of genes encoding transcription factors (Eomes, Irf8 and Maf), cytokines (Il24 and Il9) and surface receptors (Cxcr6 and Cd96), although they express the cytokine-receptor-encoding gene Il23r 9 . Thus, the 'decision' of whether a T H 17 cell will become pathogenic can be taken independently of IL-23 and might be made early during priming.
Because IL-6 is the dominant factor that initiates the transcriptional program of T H 17 cells, we speculated that intrinsic properties of IL-6 might be a major determinant of the priming of pathogenic T cells. To signal into target cells, IL-6 first binds to its receptor subunit IL-6Rα. That complex then associates with gp130 (the signaling subunit of the IL-6 receptor), which results in a heterohexameric signaling complex (IL-6, IL-6Rα and gp130 in a stoichiometry of 2:2:2) that triggers productive signaling via IL-6 into the target cell 10, 11 . In addition to its membrane form, IL-6Rα can be shed and bind IL-6 as a soluble receptor. The soluble complex of IL-6 and soluble IL-6Rα (sIL-6Rα) associates with gp130 and initiates IL-6 signaling in gp130 + cells. This type of IL-6 signaling is called 'IL-6 trans-signaling' 12, 13 . In contrast to classic IL-6 signaling, IL-6 trans-signaling can be blocked by soluble gp130, which acts as a decoy receptor for the soluble IL-6-IL-6Rα complex 14 .
Here, to investigate whether the cellular source of IL-6 was a determinant of T H 17 cell fate, we developed a novel IL-6-reporter strategy that allowed the deletion of IL-6-expressing subsets within distinct cell populations. We found that a subset of CD11b + DCs that were Sirpα + were indispensable for the priming of myelin-peptide-specific encephalitogenic T cells. Our data indicated that CD11b + Sirpα + DCs were able to trans-present IL-6 through a complex containing DC-expressed IL-6Rα bound to IL-6 that was able to interact with gp130 expressed on T cells. We define this mode of IL-6 signaling as 'cluster signaling' and propose that the 'imprinting' of encephalitogenic properties on effector T cells is dependent on IL-6 cluster signaling, while classic signaling by IL-6 through its membrane-bound receptor complex is sufficient to suppress the TGF-β-induced expression of Foxp3 but fails to prime pathogenic T H 17 cells.
RESULTS

DC-derived IL-6 is indispensable for pathogenic T H 17 cells
Because IL-6 is produced by various hematopoietic and non-hematopoietic cells, we sought to define the relevant cellular source of IL-6 for the differentiation of pathogenic T H 17 cells. We generated an IL-6-reporter knock-in allele (Il6 RD ) in which IL-6 expression is reported by expression of the cyan fluorescent protein Cerulean and alloantigen Thy1.1 (Supplementary Fig. 1 ). In addition, the reporter contains a loxP-flanked stop cassette (Stop flox/flox ) that allows celltype-specific expression of the reporter cassette depending on the driver of Cre recombinase expression used in various mouse strains. First we crossed Il6 RD/wt mice with a CMV-Cre deleter strain to allow unrestricted expression of the IL-6-reporter cassette, then we immunized the progeny of that cross with the peptide MOG in complete Freund's adjuvant (CFA) to induce experimental autoimmune encephalomyelitis (EAE). On day 7 after immunization, Thy1.1 (IL-6) was produced exclusively by CD45 + hematopoietic cells in draining lymph node cells and spleen of CMV-Cre × Il6 RD/wt mice (Fig. 1a) . CD11c + cell populations had the greatest frequency of Thy1.1 + (IL-6 + ) cells ( Fig. 1a) . Subgroup analysis revealed that expression of Thy1.1 (IL-6) was restricted to CD11b + Sirpα + CD103 − SiglecH − DCs (Supplementary Fig. 2) . We used CD11c-Cre × Il6 RD/wt × R26 Stop flox/flox YFP mice (which express yellow fluorescent protein (YFP) under control of the Rosa26 (R26) promoter after Cre-mediated deletion of the Stop flox/flox cassette to simultaneously monitor DCs (via YFP expression (under control of the R26 promoter) in CD11c + cells)) and IL-6 production in DCs (via Thy1.1 expression (under control of the endogenous Il6 promoter) in CD11c + cells). We noticed that some DCs in the draining lymph nodes of these mice were Thy1.1 + as early as the first day after immunization with MOG(35-55) in CFA ( Fig. 1b) . That subset of Thy1.1 + DCs was maintained at least through day 6 after immunization ( Fig. 1b) . At the peak of EAE (day 16 after immunization), Thy1.1 + cells in the CNS of CMV-Cre × Il6 RD/wt mice were mainly CD45 + CD11b + myeloid cells ( Fig. 1c) . Nevertheless, and in contrast to results obtained for the peripheral immune compartment, a substantial portion of IL-6 in the CNS seemed to be produced by non-hematopoietic (CD45 -) cells ( Fig. 1c) . Notably, specific ablation of IL-6-producing DCs in CD11c-Cre × Il6 RD/wt mice through the use of antibody to Thy1.1 (anti-Thy1.1) ( Supplementary Fig. 2 ) resulted in the priming of MOG(35-55)-specific T cells with reduced expression of IL-17 and increased expression of IFN-γ relative to that of the cytokine expression of MOG(35-55)-specific T cells isolated from CD11c-Cre × Il6 RD/wt mice treated with control antibody ( Fig. 1d and Supplementary Fig. 3 ). Moreover, treatment of CD11c-Cre × Il6 RD/wt mice with anti-Thy1.1 abrogated their development of EAE ( Fig. 1e) . These data suggested that either IL-6 production by DCs or the physical presence of IL-6-producing DCs was required for the induction of EAE. To distinguish between those possibilities, we conditionally deleted Il6 in DCs through the use of mice expressing CD11c-Cre and loxP-flanked Il6 alleles (Il6 flox/flox ). The loss of Il6 in DCs in CD11c-Cre × Il6 flox/flox mice (called 'Il6 ∆DC ' here) resulted in complete resistance to EAE, despite the continued presence of CD11b + Sirpα + DCs in these mice ( Fig. 1f) . Indeed, Il6 ∆DC mice were a phenocopy of Il6 −/− mice in their resistance to EAE (data not shown). Apart from its expression by DCs, some Thy1.1 (IL-6) was expressed by T cells, B cells and macrophages ( Fig. 1a) . Conditional deletion of Il6 in these cells modulated disease severity but did not abrogate the development of EAE (Supplementary Fig. 4) . Thus, DC-derived IL-6 was essential for the priming of a pathogenic T cell response in EAE.
Specific sensing of DC-derived IL-6 by interacting T cells Our data would be consistent with the idea that DC-derived IL-6 'acted back' on DCs in an autocrine manner to boost their ability to prime pathogenic T H 17 cells. However, we found no major differences between Il6ra flox/flox (control) bone-marrow-derived DCs (BMDCs) and IL-6Rα-deficient BMDCs (derived from CD11c-Cre × Il6ra flox/flox (Il6ra ∆DC ) mice, which cannot respond to soluble IL-6) in their induction of Il1b, Il12 or Il23 after exposure to exogenous IL-6 ( Supplementary Fig. 5 ). Thus, we explored alternative modes of action for DC-derived IL-6 during cognate interaction with T cells. We obtained naive (Foxp3 − ) CD4 + T cells from 2D2 × Foxp3gfp.KI mice (which have transgenic expression of a MOG(35-55)-specific TCR (2D2) and in which Foxp3 expression is reported by green fluorescent protein (GFP) (Foxp3gfp.KI)), transferred the cells into Il6 flox/flox (control) mice, Il6 −/− mice or Il6 ∆DC mice, and then immunized the host mice subcutaneously with MOG(35-55) in CFA. As previously reported 15 , priming of transgenic T cells in an IL-6-deficient environment in the Il6 −/− mice resulted in the conversion of about 20% of the 2D2 T cells into GFP + (Foxp3 + ) regulatory T cells (T reg cells) ( Fig. 2a) . In contrast, we did not observe conversion of GFP − 2D2 T cells into GFP + 2D2 T cells during the priming of naive 2D2 T cells in the Il6 ∆DC mice ( Fig. 2a) , which indicated that IL-6 from sources other than DCs was sufficient to suppress the conversion of conventional T cells into Foxp3 + T reg cells during antigen-specific priming. Indeed, the systemic IL-6 measured in the serum after subcutaneous immunization with MOG in CFA was similar in Il6 flox/flox (control) mice and Il6 ∆DC mice ( Supplementary Fig. 6 ).
Although the emergence of Foxp3 + T reg cells was suppressed equally in Il6 ∆DC mice and IL-6-sufficient (Il6 flox/flox ) mice, Il6 flox/flox mice developed EAE following immunization with MOG(35-55) in CFA, while Il6 ∆DC mice did not ( Fig. 1f) . Thus, to search for effector T cell-intrinsic features that would explain the inability of T cells primed in Il6 ∆DC mice to induce EAE, we performed RNA-sequencing analysis of GFP − (Foxp3 − ) 2D2 T cells that we isolated from the draining lymph nodes of Il6 flox/flox , Il6 −/− or Il6 ∆DC mice on day 6 after immunization with MOG(35-55) in CFA. We defined the set of genes expressed differentially in 2D2 T cells from Il6 −/− mice relative to their expression in 2D2 T cells from Il6 flox/flox (control) mice as 'IL-6 target genes' (Supplementary Table 1 ). The IL-6 target gene set was grouped as IL-6 target genes suppressed or upregulated in 2D2 T cells primed in Il6 −/− mice relative to their expression in 2D2 T cells primed in Il6 flox/flox (control) mice. By gene-set-enrichment analysis, we next identified those genes in the suppressed gene set whose expression was higher in 2D2 T cells primed in Il6 flox/flox mice than in those primed in Il6 ∆DC mice and those genes in the upregulated gene set whose expression was higher in 2D2 T cells primed in Il6 ∆DC mice than in those primed in Il6 flox/flox mice ( Fig. 2b and Supplementary Tables 2 and 3). By Ingenuity pathway analysis, we then analyzed upstream pathways compatible with the expression of A r t i c l e s those IL-6 target genes identified in 2D2 T cells primed in Il6 flox/flox mice or Il6 ∆DC mice ( Supplementary Fig. 6 ). We found that differential activation of the transcription factor STAT3 was the main pre-dictor of the distinct gene-enrichment profile of 2D2 T cells primed in Il6 ∆DC mice relative to the profile of such cells primed in Il6 flox/flox mice ( Supplementary Fig. 6 ). Moreover, when we directly assessed a published STAT3-dependent gene set 16 , expression of STAT3 target genes was overrepresented in the expression profile of 2D2 T cells primed in Il6 flox/flox mice relative to their representation in the pro-file of 2D2 T cells primed in Il6 ∆DC mice ( Supplementary Fig. 6 and Supplementary Table 4 ). Thus, we next directly assessed the activation of STAT3 in T cells in Il6 flox/flox , Il6 −/− or Il6 ∆DC mice. Naive 2D2 A r t i c l e s T cells were co-cultured with Il6 flox/flox , Il6 −/− or Il6 ∆DC splenocytes in the presence of the cognate antigen MOG . After stimulation of the cells with lipopolysaccharide (LPS), activation of STAT3 was negligible in T cells cultured with Il6 −/− APCs (Fig. 2c) . The activation of STAT3 was delayed in T cells primed with Il6 ∆DC APCs relative to its activation in T cells primed with Il6 flox/flox APCs (Fig. 2c) , despite the presence of similar amounts of soluble IL-6 in the supernatants of Il6 flox/flox APC-T cell or Il6 ∆DC APC-T cell co-cultures ( Fig. 2d) . Thus, IL-6 induced early and robust activation of STAT3 in antigenspecific 2D2 T cells only when provided by DCs.
In addition, because the in vivo priming of 2D2 T cells in Il6 ∆DC mice resulted in a highly efficient suppression of Foxp3 induction ( Fig. 2a) , we investigated whether the activation of STAT3 had differential effects on the IL-6-mediated suppression of Foxp3 expression and the induction of effector properties in conventional T cells. Naive CD44 − CD25 − CD4 + T cells from Stat3 flox/flox (control) mice or CD4-Cre × Stat3 flox/flox mice (with T cell-specific deficiency in STAT3) were activated in vitro with anti-CD3 and anti-CD28 in the presence of TGF-β with or without IL-6, followed by assessment of induction of the expression of Foxp3 and effector cytokines. As expected, STAT3 was indispensable for the induction of IL-17 expression ( Fig. 2e) . However, STAT3-deficient T cells had high expression of IFN-γ when differentiated under T H 17-polarizing conditions ( Fig. 2e,f) . The TGF-β-induced expression of Foxp3 was suppressed (at least in part) by IL-6 in STAT3-deficient T cells ( Fig. 2e,f) , which indicated that a lack of STAT3 in T cells resulted in a T H 1-cell-like phenotype under T H 17-differentiation conditions. In summary, these data suggested that T cells were able to distinguish between DC-derived IL-6 and IL-6 from other sources via different STAT3-activation kinetics, which resulted in different T cell phenotypes.
IL-6 cluster signaling is an efficient signaling mode
Beyond classic IL-6 signaling through the binding of soluble IL-6 (sIL-6) to its membrane-bound receptor, soluble IL-6-IL-6Rα complexes engage gp130 on target cells that lack IL-6Rα through the process of IL-6 trans-signaling 13 . We investigated whether during a cognate DC-T cell encounter, DC-bound IL-6Rα trans-presents DC-derived IL-6 to T cells through a distinct IL-6 trans-presentation process that requires the clustering of donating cells and receiving cells (IL-6 cluster signaling). First, we established the functionality of IL-6 cluster signaling through stable retroviral expression, in Ba/F3 cells (an IL-3-dependent mouse pro-B-cell line that lacks both endogenous IL-6Rα and gp130 expression 17, 18 ), of either IL-6Rα (lacking enhanced GFP (eGFP); thus, the cells (Ba/F3-IL-6Rα) show no GFP fluorescence) or gp130-eGFP (Ba/F3-gp130-eGFP; cells appear bright green), followed by analysis of their proliferative response to IL-6 signaling ( Fig. 3a) . While in separate cultures, Ba/F3-IL-6Rα cells (which lacked gp130) did not proliferate in response to either sIL-6 or a sIL-6-sIL-6Rα complex (called 'hyper-IL-6' here) 19 , Ba/F3-gp130-eGFP cells (which lacked IL-6Rα) proliferated in response to hyper-IL-6 but not in response to sIL-6 ( Fig. 3a) ; this suggested that hyper-IL-6 formed a functional signaling complex with membrane bound gp130-eGFP in the Ba/F3-gp130-eGFP cells. Notably, when Ba/F3-gp130-eGFP cells were co-cultured with Ba/F3-IL-6Rα cells, sIL-6 alone induced the proliferation of Ba/F3-gp130-eGFP cells (Fig. 3b,c) , which suggested that the Ba/F3-IL-6Rα cells transpresented IL-6 to the Ba/F3-gp130-eGFP cells and induced proliferation of the latter cells. This IL-6 cluster signaling required the clustering of Ba/F3-IL-6Rα cells and Ba/F3-gp130-eGFP cells in the same co-culture. Exogenous anti-IL-6Rα neutralized IL-6 cluster signaling, but soluble gp130 linked to the crystallizable fragment Fc (sgp130-Fc), a strong inhibitor of IL-6 trans-signaling by hyper-IL-6, did not (Fig. 3b) ; this indicated a functional difference between IL-6 trans-signaling and IL-6 cluster signaling. Together, these results suggested that IL-6 bound to IL-6Rα on the surface of IL-6Rα-expressing cells signaled through membrane-bound gp130 in cells that did not express IL-6Rα, when both cell types were in physical proximity.
DCs present IL-6 in trans and induce IL-6 cluster signaling Next we assessed the ability of DCs to present IL-6 in trans during a cognate interaction with T cells (Supplementary Fig. 7) . Naive (CD4 + CD44 − GFP − (Foxp3 − )) 2D2 T cells were co-cultured with BMDCs in the presence of the cognate antigen MOG and LPS to induce IL-6 production in BMDCs. GFP − (Foxp3 − ) effector 2D2 T cells showed robust activation of STAT3, as assessed by flow cytometry, when they were co-cultured with wild-type BMDCs but not after co-culture with Il6ra −/− BMDCs, although the amount of soluble IL-6 produced by wild-type BMDCs and Il6ra −/− BMDCs was similar ( Fig. 4a,b) . To determine if IL-6 cluster signaling occurred during cognate DC-T cell interactions, we co-cultured wild-type BMDCs with naive T cells isolated from either Il6ra flox/flox (control) mice or CD4-Cre × Il6ra flox/flox mice (with conditional deficiency in IL-6Rα in T cells (Il6ra ∆T )) and treated the cells with staphylococcal enterotoxin B (SEB), a superantigen that activates T cells that express a TCR with β-chain variable region 8 (V β 8 + T cells) and does so in a manner dependent on major histocompatibility complex class II (ref. 20) . V β 8 + T cells had a more intense signal for phosphorylated (activated) STAT3 than that of V β 8 − T cells present in the same culture (Fig. 4c) .
In addition, activation of STAT3 occurred in both IL-6Rα-sufficient (control) V β 8 + T cells and Il6ra ∆T V β 8 + T cells (Fig. 4c) . In contrast, exogenous soluble IL-6 induced phosphorylation of STAT3 in IL-6Rα-sufficient (control) T cells but not in Il6ra ∆T T cells (Fig. 4c) .
In addition, when 2D2 T cells (with transgenic expression of a TCR specific for MOG ) and OT-II T cells (with transgenic expression of a TCR specific for the epitope OVA(323-339) (ovalbumin amino acids 323-339)) were co-cultured with wild-type BMDCs in a triple culture, early phosphorylation of STAT3 was observed exclusively in T cells whose cognate antigen was present in the culture but not in the co-cultured T cells of irrelevant specificity ( Fig. 4d,e ); this suggested that IL-6 cluster signaling did not result in the bystander activation of T cells that did not interact with the DCs in a cognate manner.
To further characterize IL-6 cluster signaling during a DC-T cell interaction, we used a variety of IL-6-blocking reagents at the time of LPS activation of BMDCs co-cultured with 2D2 T cells in the presence of MOG . The monoclonal antibody MR16-1, which binds IL-6Rα, completely abolished the phosphorylated STAT3 signal in the 2D2 T cells (Fig. 4f) . In contrast, sgp130-Fc did not inhibit the phosphorylation of STAT3 in the 2D2 T cells (Fig. 4f) , which indicated that sgp130-Fc was unable to engage the membrane-bound IL-6-IL-6Rα complex interacting with gp130 in trans. In addition, antibodies to IL-6, and in particular mAb#8, a monoclonal antibody to IL-6 that binds the interaction site between IL-6 and IL-6Rα 10 , failed to block the activation of STAT3 in T cells in response to LPS-activated BMDCs with which the T cells were co-cultured ( Fig. 4f) .
Because IL-6 bound in a complex with IL-6Rα would be less easily neutralized by antibodies to IL-6, we investigated whether IL-6 was loaded onto IL-6Rα in the intracellular compartment and transported to the cell membrane of DCs as a complex. We incubated mixtures of equal numbers of Il6ra −/− BMDCs and wild-type BMDCs or of Il6ra −/− BMDCs and Il6 −/− BMDCs with naive (CD44 − GFP − (Foxp3 − )) 2D2 T cells in the presence of MOG(35-55) and stimulated with T cells. IL-6 cluster signaling then led to the targeted activation of STAT3 in antigen-specific T cells but not in bystander T cells.
Co-localization of IL-6 and IL-6Ra in DCs
Next we used confocal microscopy to visualize IL-6-IL-6Rα complexes in BMDCs that interacted with 2D2 T cells in a cognate manner. BMDCs were co-cultured with 2D2 T cells in the presence of MOG(35-55) and were stimulated with LPS in the absence of exogenous IL-6. We detected 'clustered' IL-6 on the surface of LPS-stimulated BMDCs interacting with 2D2 T cells, with some IL-6 located at the BMDC-T cell interaction interface (Fig. 5a) . To determine whether IL-6 and IL-6Rα interact on the surface of BMDCs, we performed a proximity-ligation assay (PLA) 21 . IL-6-deficient, IL-6Rα-deficient or wild-type BMDCs were co-cultured with 2D2 T cells in the presence of MOG(35-55) and stimulated with LPS. IL-6 and IL-6Rα were simultaneously labeled by antibodies, followed by PLA for the visualization of IL-6-IL-6Rα complexes. We detected positive PLA signals indicative of the co-localization of IL-6 and IL-6Rα at a distance of less than 40 nm in wild-type BMDC-T cell co-cultures (Fig. 5b) , while we observed only few PLA signals in Il6 −/− or Il6ra −/− BMDC-T cell co-cultures (Fig. 5b,c) ; this suggested that the background of nonspecific PLA-amplification reactions was low. Co-localization of IL-6 and IL-6Rα occurred in the cytoplasm and at the membrane the cultures with LPS. Within 120 min of LPS stimulation, the culture of Il6ra −/− BMDCs plus wild-type BMDCs elicited substantial activation (phosphorylation) of STAT3 in GFP − (Foxp3 − ) effector T cells, while the culture of Il6ra −/− BMDCs plus Il6 −/− BMDCs failed to induce early substantial phosphorylation of STAT3 in T cells, similar to 'pure' Il6ra −/− BMDCs (without Il6 −/− BMDCs) cultured with naive 2D2 T cells (Fig. 4g) ; this indicated that the Il6 −/− BMDCs, which expressed IL-6Rα, did not 'pick up' the ambient IL-6 supplied by the Il6ra −/− BMDCs and did not trans-present ambient IL-6 to T cells. Notably, the interaction of BMDCs with T cells did not result in substantial phosphorylation of STAT3 in BMDCs within 120 min (Fig. 4h) , which suggested that gp130 in the BMDCs did not sense the DC-bound IL-6-IL-6Rα complex in cis. However, there was only 'smoldering' activation of STAT3 in BMDCs beyond 120 min of LPS stimulation (Fig. 4h) . The late activation (phosphorylation) of STAT3 in BMDCs was greater in the cultures of Il6ra −/− BMDCs plus wild-type BMDCs than in the cultures of Il6ra −/− BMDCs plus Il6 −/− BMDCs (Fig. 4h) , which suggested that the larger amount of soluble IL-6 in the cultures of Il6ra −/− BMDCs plus wild-type BMDCs (data not shown) was responsible for classic IL-6 signaling into BMDCs beyond 120 min after LPS stimulation. Thus, DCs loaded IL-6 onto IL-6Rα in their intracellular compartment and used the IL-6-IL-6Rα complex to perform IL-6 cluster signaling when cognately interacting A r t i c l e s surface of wild-type BMDCs, with some signal localized at the DC-T cell interaction zone (xz projections, Fig. 5b ). Thus, we were able to visualize DC-associated IL-6-IL-6Rα complexes in DCs.
IL-6 cluster signaling during antigen-specific T cell priming in vivo
Next we investigated whether a lack of DC-mediated IL-6 cluster signaling could explain the lack of EAE development in Il6 ∆DC mice. CD11b + DCs isolated from the draining lymph nodes of wild-type mice immunized with MOG(35-55) in CFA showed surface and intracellular expression of IL-6Rα ( Fig. 6a and Supplementary  Fig. 7) . In CD11c-Cre × Il6 RD/wt × R26 Stop flox/flox YFP mice immunized the same way, the surface expression of IL-6Rα was higher in Thy1.1 + (IL-6 + ) DCs isolated from the draining lymph nodes than in their Thy1.1 − counterparts (Fig. 6b) , which indicated that DCs that expressed IL-6Rα and IL-6 simultaneously could be detected in the draining lymph nodes of the immunized mice. To investigate the requirement for DC-mediated IL-6 cluster signaling in the priming of pathogenic T cells in vivo, we immunized Il6ra ∆DC mice, which lack IL-6Rα specifically in DCs and are thus unable to trans-present IL-6 during antigen specific priming, with MOG(35-55) in CFA. In contrast to Il6ra flox/flox (control) mice, Il6ra ∆DC mice were resistant to EAE (Fig. 6c) . Thus, IL-6 cluster signaling was needed to promote the differentiation of pathogenic T cells during antigen-specific priming in a DC-proximal manner.
To assess the expression of IL-6Rα on T cells in vivo, we sorted naive (CD44 − GFP − (Foxp3 − )) T cells from 2D2 × Foxp3gfp.KI mice, transferred the cells into congenic (CD45.1 + ) host mice and then immunized host mice with MOG(35-55) in CFA. The transferred cells showed downregulation of the surface expression of IL-6Rα in the draining lymph nodes from day 1 after immunization through at least day 5, when engaged in an antigen-specific encounter, as defined by upregulation of expression of the activation markers CD69 (day 1) or CD25 (day 5) (Fig. 6d) . In addition, sgp130-Fc, which blocks IL-6 trans-signaling 22 , did not ameliorate EAE in mice with transgenic expression of sgp130-Fc relative to its severity in wild-type (control) mice (Supplementary Fig. 8) , which indicated that soluble IL-6-IL-6Rα complexes were irrelevant in EAE. We next used mice with conditional deficiency in IL-6Rα in T cells (Il6ra ∆T mice) to investigate whether IL-6Rα-deficient T cells could respond to IL-6 cluster signaling by DCs and become pathogenic effector T cells. We found a greater frequency of Foxp3 + T reg cells in the draining-lymph-node CD4 + T cell compartment of Il6ra ∆T mice immunized with MOG in CFA than in that of their Il6ra flox/flox (control) counterparts, while Il6ra ∆DC mice immunized with MOG(35-55) had a frequency of Foxp3 + T reg cells similar to that of their Il6ra flox/flox (control) counterparts (Fig. 6e) , consistent with the observation that ambient IL-6, and thus classic IL-6 signaling, provided a significant contribution to suppression of the induction of Foxp3 + T reg cells from conventional T cells in a polyclonal repertoire. Depleting Il6ra ∆T mice of T reg cells (via anti-CD25) before immunization of the mice with MOG in CFA led to a greater severity of EAE than that of Il6ra ∆T mice not depleted of T reg cells before such immunization ( Fig. 6f and Supplementary Fig. 9 ); this indicated that Il6ra ∆T T H 17 cells could be primed to become pathogenic.
Pathogenic T H 17 cells can be differentiated with IL-21 in vivo in the absence of IL-6 (refs. 15, 23) . To evaluate the contribution of IL-21 to the pathogenic priming of T cells in Il6ra ∆T mice, we adoptively transferred naive polyclonal CD4 + T cells from Il21r −/− × Il6ra ∆T mice, in which T cells are deficient in the expression of both IL-6Rα and IL-21R, into Rag1 −/− host mice, which lack endogenous mature T cells and B cells, followed by subcutaneous immunization of the host mice with MOG(35-55) in CFA. Rag1 −/− mice given transfer of Il21r −/− × Il6ra ∆T T cells mounted a T H 17 response in response to this immunization and developed EAE (Supplementary Fig. 10) . Thus, T cells lacking IL-21 responsiveness and expression of the IL-6Rα that mediates classic IL-6 signaling were still able to become pathogenic T H 17 cells.
Pathogenic T H 17 cells depend on IL-6 cluster signaling
Il6 −/− mice develop an exaggerated T reg cell response after antigenspecific priming with adjuvant 15 . Because Il6 ∆DC mice showed normal Foxp3 + T reg cell responses but did not develop EAE, we investigated whether effector T cell responses in Il6 ∆DC mice were intrinsically inefficient. Il6 flox/flox (control) mice, Il6 −/− and Il6 ∆DC mice were sensitized with MOG(35-55) in CFA and CD4 + Foxp3 − T cells were isolated from the draining lymph nodes for transcriptome analysis. Because EAE is essentially a T H 17 cell-mediated model of CNS autoimmunity, we further assessed a transcriptional module previously associated with 'non-pathogenic' T H 17 cells 8 in Foxp3 − T cells primed in the Il6 ∆DC mice. Gene-set-enrichment analysis indicated that conventional Foxp3 − T cells primed in Il6 ∆DC mice had a significantly higher expression of Il6st (which encodes gp130), Cd96 and Eomes than that of effector T cells primed in a A r t i c l e s ( Fig. 7a,b) . Notably, CD40L + Foxp3 − T cells primed in the Il6 ∆DC mice and re-stimulated with MOG(35-55) in vitro exhibited a significantly greater fraction of cells producing only IFN-γ than that of CD40L + effector T cells primed in Il6 flox/flox (control) mice (Fig. 7c) , which indicated that naive T cells primed by IL-6-deficient DCs 'preferentially' differentiated into CD96 + IFN-γ + T cells, which were incapable of inducing EAE.
In vitro, hyper-IL-6 suppressed the upregulation of CD96 expression in IL-6Rα-deficient T cells during T H 17 differentiation (Fig. 7d) , which indicated that IL-6 presented in trans was efficient in preventing the TGF-β-mediated induction of CD96 expression. We used hyper-IL-6 as a surrogate for IL-6 presented in trans and compared its effect with that of soluble IL-6 (and thus classic IL-6 signaling) during the APC-free differentiation of naive sorted (CD4 + CD44 − CD25 − ) T cells into T H 17 cells. In the presence of an equimolar amount of soluble IL-6 or hyper-IL-6, the induction of IL-17 expression in T cells was similar with each reagent (Fig. 7e) . However, the suppression of IFN-γ expression during T H 17 differentiation was significantly more efficient with hyper-IL-6 than with soluble IL-6 ( Fig. 7e) . Because under certain conditions Eomes is an inducer of IFN-γ in CD4 + T cells 24, 25 , we investigated whether the greater fraction of IFN-γ + T cells induced by TGF-β plus soluble IL-6 was due to high Eomes expression. During T H 17 differentiation, the expression of Tbx21 mRNA (which encodes the transcription factor T-bet) and, in particular, Eomes mRNA was suppressed less efficiently by IL-6 than by hyper-IL-6, with no modulation of the expression of Rorc mRNA (which encodes the transcription factor RORγt) (Fig. 7f) . Conversely, hyper-IL-6 was significantly more potent than soluble IL-6 in inducing robust expression of GFP (IL-23R) during the in vitro T H 17 differentiation of naive CD4 + T cells isolated from reporter mice in which a A r t i c l e s GFP-reporter-encoding cassette is knocked into the Il23r locus (Il23r gfp/+ ) 26 (Fig. 7g,h) . These data indicated that the higher IFN-γ expression in T cells primed in Il6 ∆DC mice was linked to lack of IL-6 trans-presentation in these mice.
Because high IFN-γ expression in myelin-specific-T cells is associated with protection against EAE 27 , we investigated whether the high IFN-γ expression observed in Foxp3 − effector T cells in the Il6 ∆DC mice might determine the resistance of Il6 ∆DC mice to EAE. As measured A r t i c l e s by dye dilution, 2D2 T cells primed in Il6 ∆DC mice proliferated as well as 2D2 T cells primed in Il6 flox/flox (control) mice did, but the former showed more production of IFN-γ ( Fig. 8a,b) . Neutralization of IFN-γ in Il6 ∆DC mice with monoclonal antibody to IFN-γ fully restored the susceptibility of Il6 ∆DC mice to EAE and resulted in EAE of even greater severity than that of Il6 flox/flox (control) mice treated with a control antibody (Fig. 8c) . In summary, these data indicated that priming of T H 17 cells in Il6 ∆DC mice in the absence of DC-mediated IL-6 cluster signaling resulted in exaggerated expression of IFN-γ in CD4 + T cells, most probably due to aberrant activation of STAT3 in these cells.
DISCUSSION
Here we found that T cells responded to IL-6 in the absence of IL-6Rα expression through a process that we have called 'IL-6 cluster signaling' , in which DC-membrane-bound IL-6Rα in complex with IL-6 was presented in trans and was sensed by gp130 molecules expressed on T cells. IL-6 cluster signaling not only replaced classic IL-6 signaling but led to qualitatively different T cell responses. The prototypic cytokine to be trans-presented by auxiliary cells via its high affinity receptor is IL-15 (ref. 28) . It is likely that similar to IL-15, IL-6 is loaded onto IL-6Rα in endosomal compartments. Trans-presentation has also been proposed for another member of the IL-6 family, cardiotrophin-like cytokine, through binding to the receptor for ciliary neurotrophic factor 29 . Although IL-6 forms a stable complex with soluble IL-6Rα, the affinity of IL-6 for IL-6Rα is only about 0.5-1 nM (ref. 13 ) and thus is two orders of magnitude lower than the affinity of IL-15 for IL-15Rα. However, membrane-bound-cytokine trans-presentation has also been reported for IL-2, whose affinity for IL-2Rα is in the same range as the affinity of IL-6 for IL-6Rα 13, 30 .
During interactions with T cells, DC-mediated IL-6 cluster signaling restricted the IL-6 signal to cognate T cells, with high temporal synchronization with the TCR signal. Such coordination of signals led to the 'imprinting' of pathological properties on the recipient T cells. Notably, suppression of Foxp3 was induced in T cells with diminished or even absent STAT3 signaling and could be fully supported by classic IL-6 signaling. Therefore, the IL-6 that prevented the upregulation of Foxp3 expression in T cells did not have to be derived from the priming DC and could be derived in soluble form from the 'micro-milieu' . Hence, it is possible that the suppression of the induction of Foxp3 expression in T cells occurs as a 'bystander' effect of ambient IL-6. However, the IL-6-dependent induction of inflammatory properties in Foxp3 − T cells is efficient only in the context of antigen presentation and probably does not occur as a bystander effect of ambient IL-6. This suggests that IL-6-mediated pathogenic T cell differentiation passes through two checkpoints: the suppression of Foxp3 induction via classic IL-6 signaling, and the initiation of a pathogenic effector T cell transcriptional program via IL-6 cluster signaling. Therefore, the ability to induce pathogenic T H 17 cells is dependent on APCs that can co-present IL-6 in trans.
Here we found that the IL-6 + IL-6Rα + DCs that were able to perform cluster signaling were CD103 − and belonged to the subset of CD11b + Sirpα + DCs that have been classified as 'cDC2' 31 and have been associated with pathogenic T H 17 responses 32 . As a mechanistic basis for the ability of this DC subset to 'instruct' T H 17 responses is lacking, we propose that IL-6 cluster signaling synchronized with antigen presentation might represent the instructive cue for the development of pathogenic T H 17 cells. IL-6 cluster signaling led to earlier and more robust expression of IL-23R in antigen-activated T cells than did classic IL-6 signaling. Therefore, facilitated sensing of IL-23 further supports their pathogenic phenotype 33 . In contrast, in the absence of IL-6 cluster signaling, IL-23 is unable to compensate for the impaired initiation of a pathogenic transcriptional program in antigen-specific T cells, which suggests that the synchronization of antigen-specific priming and IL-6-mediated STAT3 signaling is fundamental for the pro-inflammatory phenotype of T cells. Because T cell blasts extensively downregulate their surface expression of IL-6Rα, it is plausible that IL-6 cluster signaling is a means of combining a 'pathogenic' IL-6 signal with cognate re-activation. The APC type and the anatomical compartment of this process have not been defined precisely.
We have provided evidence that lack of IL-6 cluster signaling during T H 17 priming deviated the cytokine phenotype into IFN-γ production, which was dependent in part on Eomes expression. Although there has been some controversy in this area 34 , IL-6 has been shown to suppress the development of T H 1 cells via direct and indirect mechanisms 35 .
Here we demonstrated that IL-6 cluster signaling in particular was an efficient means of preventing the induction of IFN-γ during helper T cell differentiation. In our model, in the absence of IL-6 cluster signaling, insufficient activation of STAT3, and thus a STAT1-STAT3 imbalance, allowed the expression of Eomes and IFN-γ in T H 17-priming conditions and resulted in impaired encephalitogenicity.
Finally, the possibility of IL-6 cluster signaling has implications for therapeutic interventions. Anti-IL-6 failed to inhibit IL-6 cluster signaling. The IL-6-IL-6Rα complex formation occurred within DCs, most probably followed by targeted shuttling to plasma-membrane regions involved in the cognate interaction with T cells, with immediate A r t i c l e s accessibility to gp130 molecules on the T cell side. Therefore, site I of the IL-6 molecule 10 , which mediates the binding of IL-6 to IL-6Rα and is targeted by most antibodies to IL-6, is already buried in the IL-6-IL-6Rα complex when it appears at the plasma membrane. Although sgp130-Fc suppresses IL-6 trans-signaling 14 , IL-6 cluster signaling was not inhibited by sgp130-Fc; we hypothesize that sgp130-Fc cannot access the IL-6-IL-6Rα complex at the DC-T cell interaction zone. However, similar to classic IL-6 signaling and IL-6 trans-signaling, IL-6 cluster signaling remained amenable to neutralization via anti-IL-6Rα. Thus, IL-6-targeting strategies must be carefully re-evaluated for differential signaling modalities in the design of therapeutic strategies for autoimmunity, chronic inflammation and cancer.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
Il6 ∆DC mice in the presence of 50 µg/ml MOG . For some experiments, naive 2D2 and OT-II T cells were pre-cultured with BMDCs in the presence of either MOG or OVA(323-339) (ISQAVHAAHAEINEAGR; Auspep, Tullamarine, Australia). LPS (0.5 µg/ml) was added, and cells were harvested at the time points for analysis indicated in the figures and legends.
In some experiments, the matrix-metalloproteinase inhibitor Marimastat (3 µM, Sigma-Aldrich) was added to block IL-6Rα shedding. To analyze different IL-6 signaling modes, blocking agents were added: anti-IL6 (polyclonal goat IgG, R&D # AF-406-NA or monoclonal mAb#8 (ref. 43)), anti-IL6Rα (MR16-1), or sgp130-Fc 14 , all at 1 µg/ml. For intracellular cytokine staining, cells were re-stimulated with 50 ng/ml PMA (Sigma-Aldrich), 1 µg/ml ionomycin (Sigma-Aldrich) and monensin (1 µl/ml BD GolgiStop) at 37 °C for 2.5 h. Subsequent to live/dead and surface staining, cells were fixed and permeabilized (Cytofix/Cytoperm and Perm/Wash Buffer; BD Biosciences), and stained for cytokines IL-17A (TC11-18H10.1; 1:100; BioLegend), IFN-γ (XMG1.2; 1:200; eBioscience), IL-10 (JES5-16E3; 1:100; BD Biosciences), and GM-CSF (MP1-22E9; 1:100;, BD Biosciences). For intracellular staining of IL-6 in BMDCs, cells were stimulated with TLR ligands for 3 h before adding 5 µg/ml Brefeldin A (Sigma-Aldrich) for further 2 h. Subsequent to live/dead and surface staining, fixation and permeabilization, cells were stained for IL-6 (MP5-20F3; 1:100; BD Biosciences). For intranuclear staining of Foxp3 (FJK-16s, eBioscience; 1:100), cells were stained for live/dead discrimination and surface markers. Fixation, permeabilization, and intranuclear staining were performed according to the manufacturer's instructions (Transcription Factor Staining Buffer Set, eBioscience). To analyze STAT3 activation, cells were fixed with Phosflow Lyse/Fix Buffer (BD) for 10 min at 37 °C, permeabilized with PhosFlow Perm Buffer III (BD) for 30 min on ice and stained simultaneously for surface markers and STAT3 phosphorylated at Tyr705 (4/P-STAT3; 1:20; BD Biosciences) according to the manufacturer's instructions. Cells were analyzed using a CyAn ADP 9 flow cytometer (Beckman/Coulter) and FlowJo software (Tree Star).
